PathAI

ONCOLOGY

AI Products

Advancing Precision Medicine with Digital Pathology and Artificial Intelligence

Transform routine pathology samples into standardized and structured pathology insights to empower oncology research & drug development



Experience pathology through the lens of AI

Quantify what you see and discover what you cannot

Visualize Pathology with Pixel-Level Precision



Artifact Detection | Tissue Segmentation | Cell Classification

Explore & Extract Quantitative Pathology Insights

H&E ID	AREA of CANCER	TOTAL LYMPHOCYTES in CANCER STROMA	RATIO of LYMPHOCYTES to FIBROBLASTS in TUMOR
257785	27.355	3611	12.503
257682	32.699	18822	7.405
257722	17.855	2974	5.396
257812	24.049	3426	8.131
257664	37.703	2281	2.764
257779	86.544	13325	9.771

Identify

tissue regions, cell types, nuclear morphologies, staining profiles, & more

Quantify

biomarker expression & drive standardization of precision diagnostics

Discover

novel histological features & multi-modal biomarkers to fuel drug development

Leverage the power of AI at every phase of drug development

Drug Discovery

Accelerated evaluation and optimization of drug safety and efficacy in animal models to expedite pre-clinical development and asset selection

Clinical Development

Discover novel pathology and multi-modal biomarkers for patient stratification. Improve biomarker quantification and standardization to expedite clinical development

Launch & Approval

Develop and commercialize AI-powered medical devices and clinical decision support tools to accelerate and enhance precision medicine strategies

Explore Suite

AIM Suite

End-to-end AI pathology solutions to **Discover Biomarkers** that translate to **Clinical Impact**



Path**Explore**™

Spatially-resolved, single-cell analysis of the tumor micro-environment directly from H&E whole slide image & immuno-oncology phenotyping with **PathExplore™ IOP**



IHC **Explore**™

Sub-celluar quantification of IHC assays across disease indications and drug targets for next-generation biomarkers

AIM-HER2



AIM-PD-L1



AI Measurement **(AIM)** products streamline pathologist workflows and drive standardization of biomarker scoring for potential use in:

- End Point Assessment
- Patient Enrollment
- Biomarker QC

Learn more at **www.pathai.com**

Contact us at **bd@pathai.com**

Demo the platforms: **info.pathai.com/pathai-demo-the-platforms**

PathExplore™, PathExplore™ IOP, IHC Explore™, AIM-HER2, and AIM-PD-L1 are for research use only. Not for use in diagnostic procedures.

www.pathai.com
1325 Boylston Street Suite 10000 Boston, MA 02215